Virus Filtration in Biomanufacturing: A Patent Landscape for 2026
78.8% concentration. The top five assignees hold 298 of 378 records in scope — a field with a narrow, entrenched leadership group. Filings rose from 12 in 2017 to a peak of 75 in 2023. The 2021→2024 span shows +4% growth — essentially flat once you account for the record volume involved. 2025 and 2026 figures are undercounted because publication lags filing by roughly 18 months; treat the most recent two years as incomplete, not as a decline.
- 1REGENERON PHARMACEUTICALS INC81
- 2AMGEN INC70
- 3GENENTECH INC67
- 4F HOFFMANN LA ROCHE & CO AG43
- 5EMD MILLIPORE CORP37
See the full virus filtration in biomanufacturing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about virus filtration patents
How concentrated is the virus filtration patent landscape?
It is highly concentrated. Across 378 records in scope, the top five assignees together hold 298 records, or 78.8% of the field, and the top ten reach 98.4%. That leaves the remaining ranked companies, out of 24 total, with only a handful of filings each. Anyone assessing freedom to operate in this space should expect to be reviewing claims from a small set of large biomanufacturers and filter manufacturers rather than a fragmented field of many small filers.
Is patent filing activity in virus filtration growing or slowing down?
Filings rose steadily from 12 in 2017 to a peak of 75 in 2023, and the 2021-to-2024 span shows a modest +4% growth rate. The apparent drop in 2025 and 2026 is not a real slowdown — publication typically lags filing by around 18 months, so the most recent one to two years in any patent dataset are always undercounted. The fairer read is that filing activity plateaued after 2023 rather than declined.
What patent classes dominate virus filtration claims?
C07K, covering peptides and proteins, appears on 62.2% of the 378 records in scope, making it the single most common class. C12M (bioreactor and enzyme apparatus) and B01D (separation processes, including filtration) follow at 29.9% and 28.6% respectively. Because records can carry multiple IPC classes, these figures overlap rather than sum to 100%, reflecting that most filings combine a biological composition claim with a filtration or apparatus claim.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Virus Filtration in Biomanufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.